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Abstract: The yellow pigment curcumin, extracted from turmeric, is a renowned polyphenol with a
broad spectrum of health properties such as antioxidant, anti-inflammatory, anti-cancer, antidiabetic,
hepatoprotective, anti-allergic, anti-dermatophyte, and neuroprotective. However, these properties
are followed by a poor pharmacokinetic profile which compromises its therapeutic potential. The
association of low absorption by the small intestine and the extensive reductive and conjugative
metabolism in the liver dramatically weakens the oral bioavailability. Several strategies such as
inhibition of curcumin metabolism with adjuvants as well as novel solid and liquid oral delivery
systems have been tried to counteract curcumin poor absorption and rapid elimination from the body.
Some of these drug deliveries can successfully enhance the solubility, extending the residence in
plasma, improving the pharmacokinetic profile and the cellular uptake.
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1. Introduction
Curcumin is a yellowish pigment and a well-known polyphenol found in the rhizome of turmeric
and other Curcuma spp. Curcumin is usually present in the plant of the Zingiberaceae family with
the related compounds demethoxycurcumin, bis-demethoxycurcumin, and cyclo-curcumin (Figure 1,
green box). Together, these four compounds are referred to as curcuminoids [1]. Noticeable, for
curcuminoid content in the roots, are the species Curcuma zedoaria (>100 µg/g), Curcuma longa (1–2 µg/g)
and Curcuma aromatica (0.1 µg/g) [2].
Curcumin, chemically known as [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione]
or diferuloylmethane, exhibits keto-enol tautomerism dependent on the solution pH: at pH < 7 the
keto-form is the principal, while at pH > 7 it occurs in the enol form [3].
Curcumin is reported to have three different pKa values: the first (pKa 7.7–8.5) and second
(pKa 8.5–10.4) values are from the two phenolic hydroxy groups, and the third (pKa 9.5–10.7)
value is from the enolic proton [1]. It is chemically stable between pH 1–6, but it is practically
insoluble in water in this pH range. Autoxidation reaction, occurring a physiological pH, lead
to a series of bicyclopentadione products (Figure 1, blue box) in which the 7-carbon chain has
undergone oxygenation and double cyclization. Early autoxidative degradation products mediate the
activity on topoisomerase, target of many chemotherapy agent already present in clinical practice [4].
Another minor pathway of cleavage which take place in alkaline media with the degradation into
trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexenal and secondly into vanillin, ferulic acid,
and feruloyl-methane (Figure 1, orange box). Stability is indeed related to the undissociated form of the
hydroxy groups [2]. Oxidative degradation and modification can also be induced by light absorption
(photo-degradation). Degradation reactions dramatically change curcumin structure and properties
affecting its pharmacokinetic and pharmacodynamic behavior [5].
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In Curcuma longa, crude extract curcuminoid makes up 1–6% of turmeric by weight, distributed in
60–70% curcumin, 20–27% demethoxycurcumin, and 10–15% bis-demethoxycurcumin [6] whereas
commercially available curcumin contains about 77% in curcuminoids [2].
Turmeric has been traditionally used as a dye, a spice, and as an anti-inflammatory remedy in both
Indian and Chinese medicine. The variety of health properties such as antioxidant, anti-inflammation,
anti-cancer, antidiabetic, hepatoprotective, anti-allergic, anti-dermatophyte, and neuroprotective effects
have been attributed to curcumin, the active principle of turmeric [7,8]. From a molecular point of
view, curcumin may mediate its pharmacological activities through Janus kinase/signal transducers
and activators of transcription (JAK-STAT), nuclear factor kappa B (NF-kB), protein kinase B (AKT or
PKB), transforming growth factor b (TGF-b), and mammalian target of rapamycin (mTOR) [7,9–13].
In particular, the transcription factor Nrf2 and NF-kB regulate: (1) the inhibition of the transcription
factor NF-kB mediates anti-inflammation and (2) the induction of Nrf2 signalling pathways promotes
antioxidant defence mechanisms and production of phase II enzymes [2]. Anticarcinogenic effects of
curcumin are also related to an increase in the p53 levels and thus in pro-apoptotic Bax and cytochrome
C. The suppression of proliferation and a cell-cycle arrest can be modulated by curcumin also through
p53 independent pathway such as the inhibition of NFkB inhibitor a (IkBa), B-cell lymphoma 2 (Bcl-2),
B-cell lymphoma-extra large (Bcl-xl), cyclin D1, and interleukin 6 (IL6). Moreover, apoptosis can be
initiated by curcumin by the increased cleavage of poly(ADP-ribose) polymerase (PARP) [2].
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Figure 1. Chemical structures of curcuminoids (green box): (1) Curcumin keto-form,
(2) Curcumin enolic-form, (3) demethoxycurcumin, (4) bis-demethoxycurcumin, and (5)
cyclo-curcumin. Chemical structures of curcumin degradation products (orange box): (6)
trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexenal, (7) vanillin, (8) ferulic acid, and (9)
feruloyl-methane. Chemical structures of some curcumin autoxidation products (blue box): (10)
bicyclopentadione, (11) vinylether, and (12) spiroepoxide.
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2. Poor Pharmacokinetic Profile of Curcumin after Oral Intake
It is well accepted that curcumin itself displays poor solubility in water, chemical instability, and a
lowly pharmacokinetic profile. Despite its efficacy and safety, the therapeutic potential of curcumin is
indeed still debated due to a relatively poor bioavailability in humans, even when administered at
high dosage (12 g/day) [14]. Generally, the oral bioavailability of curcumin is low due to a relatively
low absorption by small intestine coupled to an extensive reductive and conjugative metabolism in the
liver and an elimination through the gall bladder. The poor bioavailability is also exacerbated by the
curcumin bindings to enterocyte proteins that can modify its structure [5].
The bioavailability of nutraceuticals is a function strictly dependent on transformation in the
gastrointestinal tract and bioaccessibility. The transformation refers to the amount of compound that
remains in a bioactive form in the intestinal phase, whereas bioaccessibility is the amount of active
compound accessible for absorption. Bioavailability, indeed, is the product of these two factors [15].
2.1. Metabolism
Curcumin undergoes extensive phase I and II biotransformation (Figure 2). The liver is indicated
as the primary site of metabolism for curcumin, together with intestine and gut microbiota [16].
Curcumin’s double bonds are subsequently reduced in enterocytes and hepatocytes by a reductase to
dihydrocurcumin, tetrahydrocurcumin, hexa-hydrocurcumin, and octahydrocurcumin.
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Figure 2. Curcumin phase I and II metabolism in a living organism. Curcumin (A) undergoes
several reactions of reduction by a reductase (2) to dihydrocurcumin (B), tetrahydrocurcumin (C),
hexahydrocurcumin (D) and octahydrocurcumin (E). Curcumin can be both conjugating to any of the
hydroxyl groups, with glucuronic acid by glucuronosyltransferase (1) or sulfate by sulfotransferase
(3). Phase II products are the followings: curcumin glucuronide (M), dihydrocurcumin glucuronide
(N), tetrahydrocurcumin glucuronide (O), hexahydrocurcumin glucuronide (P), curcumin sulfate (F),
dihydrocurcumin sulfate (G), tetrahydrocurcumin sulfate (H), hexahydrocurcumin sulfate (I), and
octahydrocurcumin sulfate (L). In structure N, O, P ‘gluc’ is referred to as glucuronic acid.
Moreover, secondary biliary metabolism was dihydro-ferulic acid and ferulic acid [2,14]. Phase
II metabolism is quite active, in the intestinal and hepatic cytosol, on both curcumin and its
phase I metabolites especially by conjugation with glucuronic acid and sulfate at the phenolic
site. Curcumin is sulfated by SULTs in the cytosol, mainly SULT1A1 and SULT1A3, whereas UGTs
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catalyse the glucuronidation of curcumin in the intestinal and hepatic microsomes. Dihydrocurcumin,
tetrahydrocurcumin, and hexa-hydrocurcumin exist in both free-forms or as glucuronides [2,6,14,16].
Curcumin also undergoes an alternative metabolism by intestinal microbiota such as Escherichia
coli and Blautia sp. Escherichia coli was found to be active by an NADPH dependent reductase in a
two-step reduction pathway from curcumin to dihydrocurcumin then to tetrahydrocurcumin [17].
Blautia sp. produces curcumin demethylation into two derivatives: demethylcurcumin and
bis-demethylcurcumin [18]. Interestingly, several studies report that the poly-pharmacology of
curcumin can be attributed to its metabolites, which are recognized as anti-oxidant, anti-inflammatory,
antitumor, cardioprotective, and anti-diabetic [5,19–24].
2.2. Absorption, Bioavailability, and Tissue Concentration
Several studies have been performed using curcumin oral supplement to investigate its absorption
in both human and laboratory animals.
Curcumin was prescribed orally for three months in 25 patients with high-risk or pre-malignant
lesions. Patients enrolled for this study presented one of the following pathologies: resected urinary
bladder cancer, arsenic Bowen’s disease of the skin, uterine cervical intraepithelial neoplasm, oral
leucoplakia, and intestinal metaplasia of the stomach. Curcumin’s serum peak was found at 1 to 2 h
after oral intake. Then gradually declined within 12 h. The average serum concentrations after taking 4,
6, and 8 g of curcumin were 0.51 ± 0.11 µM, 0.63 ± 0.06 µM, and 1.77 ± 1.87 µM, respectively. Excretion
of curcumin in urine was inappreciable [25].
Healthy volunteers (n = 24) were administered with a single dose of curcumin standardized
powder extract with doses ranging from 0.5 to 12 g. The dose was followed by a cup of water and
a standard meal containing dietary fat. No curcumin was detected in the serum of participants
administered with a dose inferior to 8 g. In 2/24 subjects, curcumin was found at a level of about 30 (1
h), 40 (2 h), and 50 (4 h) ng/mL after a dose of 10 g whereas level of about 30 (1 h), 60 (2 h), and 50 (4 h)
ng/mL after a dose of 12 g [26].
Patients (n = 15) with chemotherapy-refractory colorectal cancer received Curcuma extract daily
for up to 4 months at doses between 0.4 and 2.2 g/day, containing 36–180 mg of pure curcumin.
Curcumin was recovered only in faeces after 29 days from consumption with a concentration at about
64 and 1054 nmol/g depending on dosage (1.7 to 2.2 g of extract or 144 to 180 mg of curcumin). In both
blood or urine curcumin or its metabolites were not detectable [27].
Another study on chemotherapy refractory colorectal cancer (n = 15) showed measurable levels
of curcumin after doses between 0.45 and 3.6 g daily for up to 4 months. Curcumin was detected in
plasma samples, after a dose of 3.6 g/day, at the 1 h time points on days 2, 8, and 29 of intervention
with a mean of 11.1 ± 0.6 nmol/L. In these samples also, glucuronides (15.8 ± 0.9 nmol/L) and sulfates
(8.9 ± 0.7) of curcumin were found. Moreover, patients under 3.6 g of curcumin daily displayed urinary
levels between 0.1–1.3, 19–45, and 210–510 nmol/L of curcumin, curcumin sulfate, and glucuronides,
respectively [28].
Patients with hepatic metastases from colorectal cancer (n = 12) received orally 0.45–3.6 g of
curcumin daily, for one week before surgery. Trace levels (<0.01 µM) of curcumin and its conjugates
(sulfate and glucuronide) were only found in liver and portal circulation [29].
Patients (n = 12) with confirmed colorectal carcinoma received 0.45, 1.8, or 3.6 g of curcumin daily,
for seven days before colectomy displayed a poor concentration in the blood (<0.3 nmol/L). Levels of
curcumin in normal and malignant colorectal tissue ranged from 0.9 to 20 nmol/g tissue depending on
doses [30].
Another study enrolled healthy human volunteers to study curcumin pharmacokinetics after a
single oral dose of 10–12 g. Free curcumin was detected in the plasma of only one subject after 30 min
from the administration. The concentrations of curcumin glucuronide and curcumin sulfate at Tmax
at the 10 g dose level were 2.04 ± 0.31 µg/mL and 1.06 ± 0.40 µg/mL and at the 12 g dose level were
1.40 ± 0.74 µg/mL and 0.87 ± 0.44 µg/mL, respectively [31].
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Another study in human volunteers (n = 4) was undertaken to investigate the pharmacokinetics
of curcumin taken in turmeric-containing food: a sandwich made from turmeric-containing bread and
a portion of soup, plus a sweet oat bar. Each subject consumed 3 g turmeric in total (approx. 100 mg of
curcumin). Curcumin was investigated in plasma and detected in only 1/4 volunteers with a Cmax of
3.2 nM at 2 h post-food ingestion. Significant metabolites of curcumin including curcumin glucuronide,
demethoxycurcumin glucuronide, and curcumin sulfate were detected in all four volunteers with a
Cmax 47.6 ± 28.5 nM, Cmax 1.9 ± 1.2 nM, and Cmax 2.1 ± 1.7 nM respectively. These concentrations were
achieved at 30 min post-food [32].
The viability of oral curcumin was also evaluated in gemcitabine-resistant patients with pancreatic
cancer (n = 21) who received 8 g oral curcumin daily in combination with chemotherapy. Curcumin
pharmacology was studied in n = 5 patients heterogeneous in terms of duration of curcumin treatment
and time of blood draw after final curcumin intake. Total curcumin levels (comprehensive of phase II
metabolites) ranged from 29 to 91 ng/mL, except for one patient who demonstrated a plasma curcumin
level of 412 ng/mL (3 months of curcumin intake, curcumin titration was done 4 h after the final dose).
This high plasma level was probably due to a decreased clearance of curcumin caused by constipation
related to peritonitis carcinomatosa [33].
Another study on pancreas adenocarcinoma was done in which patients (n = 21) received daily
8 g of oral curcumin, with restaging every two months. In patients, (n = 19) curcumin pharmacokinetic
profile was studied, and no free curcumin was detected in any of these. Conjugated curcumin was
found to range between 0–125 ng/mL (2 h), 1.8–117.0 ng/mL (24 h), and 22–41 ng/mL (after 3 days) [34].
Chinese patients (n = 34) who present a decline in memory and cognitive function underwent
six months of treatments with curcumin (1 g or 4 g daily). The maximum concentration in total
curcuminoids was 92 ± 29 ng/mL [35].
The tolerability and efficacy in Alzheimer disease were also evaluated in patients (n = 36) who
receive placebo, 2 grams/day, or 4 grams/day of oral curcumin for 24 weeks. The plasma levels of
native curcumin and glucuronide were about seven ng/mL and 96 ± 26 ng/mL, respectively [36].
Levels of curcuminoids were quantified in colorectal mucosa of patients (n = 24) undergoing
colorectal endoscopy or surgical resection. Fourteen days before endoscopic biopsy or colonic resection
2.35 g curcumin was administered. Curcuminoids were detectable in plasma samples (9/24), urine
(24/24), and the colonic mucosa (23/24). Plasma levels of parent curcumin were 12.2 ng/mL and
glucuronides 4.9 ng/mL. Tissue biopsies presented 48.4 mg/g (127.8 nmol/g) of curcumin which was
demonstrated to persist in the mucosa for up to 40 h post-administration. In colorectal mucosa,
samples were also detected curcumin metabolites and the other curcuminoids (demethoxycurcumin,
bis-demethoxycurcumin).
The effects of oral curcumin (2 g or 4 g per day for 30 days) was assessed in 44 eligible smokers
with eight or more aberrant crypt foci on screening colonoscopy. Concentrations of curcumin and
curcumin conjugates were assayed in rectal mucosal biopsies and venous plasma. Tissue levels ranged
from 3–11 µg/g protein and in blood 2.9–4.7 ng/mL. In plasma also curcumin conjugates were detectable
ranging from 9.2–382.7 [37].
Curcumin, even though it displays poor oral bioavailability, due to its lipophilicity is able to
cross the blood–brain barrier. Thus, is able to reach brain in biologically effective concentrations
promoting neuroprotection. It should be noted that curcuminoid entry into the brain only if they
are not glucuronidated. Very few studies, only in murine models, were realized to find its brain
concentration. Mice administered 50 mg/kg curcumin by oral dose displayed a brain concentration
inferior than limit of detection at 30, 60, 120 min after the administration. By contrast, with 100 mg/kg
curcumin by intraperitoneal injection the concentration ranged between 4–5 µg/g tissue in a period
between 20–40 min [38]. Mice chronically fed (4 months with 2.5–10 mg/day) with curcumin showed
0.5 µg/g tissue after oral administration, higher concentrations were reached with intraperitoneal and
intramuscular administration [39].
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Taken into consideration all these data, the administration of crude curcumin displayed a
wide-ranging serum concentration from 1 to 3200 ng/mL depending on dose, ranging from 2 to 10 g,
and subject’s physiology. In some cases, its concentration is under the instrumental limit of detection
(<1 ng/mL) even with a dose of 3.6 g [30]. Thus, the choice of high-performance instrumentation, such
as liquid chromatography coupled to mass spectrometry (LC-MS/MS), seemed to be fundamental for a
correct curcumin pharmacokinetics determination.
3. Factors Impacting on Oral Curcumin Bioavailability
Polyphenols bioavailability in dietary sources can be affected by either origin, food processing, and
macronutrients. Their levels and profile patterns depend, not only on the types of fruits and vegetables
but also on climate, soil, plant stresses, ripening, and storage. Food processing such as grinding, drying
and heating changes the food matrix and thus polyphenols composition. Moreover, macronutrients,
especially dietary lipids, may affect curcumin solubility and absorption. Turmeric should be in cuisine
associated with lecithin-rich ingredients like eggs or vegetable oils, in order to increase the dietary
intake of curcuminoids (J. Cuomo et al., 2011). Moreover, powdered curcuminoids incorporated into
buttermilk (300 mg curcuminoids/100 g of buttermilk, 0.3%), before yogurt manufacturing, resulted
in increased in bioaccessibility (15-folds) of curcuminoids compared to that of neat curcuminoids.
However, the enhanced bioaccessibility of curcuminoids in yogurt was still low (approximately 6%)
(Fu et al., 2016). Digestive steps also contribute to low bioavailability of polyphenols affecting solubility,
degradation in the intestinal environment, and the permeation rate in the small intestine.
There is evidence to suggest that gender can have a significant influence on curcumin
pharmacokinetics. These differences may be due to gender-specific factors such as (1) increased
clearance in men due to a higher activity of hepatic drug efflux transporters and (2) higher body fat
in women [32,40]. Plasma levels, following administration of different oral curcumin formulation, to
healthy human volunteers were 1.4 to 2.1 higher in women vs. men, depending on formulation [40]. By
contrast, in another study which involved only one woman, plasma levels of the curcumin metabolites
were all lower than in the male (n = 3) study participants (e.g., curcumin glucuronide 53.7 vs. 26.3 nM,
curcumin sulfate 2.6 vs. 0.7 nM in male vs. female respectively) [32].
4. Enhancing Bioavailability of Oral Curcumin
In order to counteract poor curcumin absorption and rapid elimination from the body several
strategies have been attempted such as the inhibition of curcumin metabolism with adjuvants as well
as novel solid and liquid oral delivery systems. These novel drug delivery systems (Table 1) could
overcome the pharmaceutical issue related to curcumin delivery enhancing the solubility, extending
the residence in plasma, improving the pharmacokinetic profile and the cellular uptake [41,42].
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Table 1. Enhancing bioavailability of oral curcumin by different novel delivery systems.
Formulation Subjects 1 Curcumin Dose Pharmacokinetics Parameters (Curcumin) 2 Ref.
Curcumin +
piperine
H 2 g + 5 mg 6.92 ng/mL (mean) [14]
H 4 g + 24 mg 136–176 ng/mL (range) [43]
H 2 g/kg + 20 mg/kg 180 ng/mL at 0.75 h [44]
Curcumin +
lecithin
H 400 mg 50.3 ± 12.7 ng/mL at 3.8 ± 0.6 h [45]
H 200 mg 24.2 ± 5.9 ng/mL at 4.2 ± 0.8 h [45]




H 30 mg 1.8 ± 2.8 ng/mL [47]
H 376 mg 27.3 ± 6.4 ng/mL at 1.4 h [48]
H 30 mg 25.5 ± 12.2 ng/mL [49]
P Multiple doses of 200 or400 mg/day
324 ng/mL with a dose of 200 mg of Theracurmin
and 440 ng/mL with a dose of 400 mg [50]
H 150 or 210 mg 189 ± 48 ng/mL with a dose of 150 mg and 275 ±7 ng/mL with a dose of 210 mg [51]
Curcumin in solid
lipid particle
H 650 mg (135–195 mgcurcumin) 22.4 ng/mL at 2.4 h [52]
P From 2 to 4 g 30–40 ng/mL between 2 to 4 h [52]
Curcumin in
micellar system
H 500 mg 1189 ng/mL at 1.1 h [40]
P 210 mg/day per 4 days 253 ng/mL (total curcuminoids) [53]
Miscellaneous
H 500 mg Cureit 74.3 ng/mL [54]
H 4 × 500 mg capsules ofBiocurcumax™ 689.18 ng/g at 4.6 h [55]
1 H: healthy volunteers P: patients. 2 In here is reported the maximum concentration of curcumin in systemic blood
otherwise when the data was not shown, the range or the mean of curcumin concentration were implemented.
4.1. Combination of Curcumin and Piperine
A natural product capable of modifying curcumin disposition and bioavailability is piperine, the
natural alkaloid of black pepper (Piper nigrum), which is a potent inhibitor of biotransformation and
especially glucuronidation. The association of 2 g of curcumin + 5 mg of piperine displayed a 3-fold
increase [14], with respect to pure curcumin. Pharmacokinetics of curcumin+piperine (4 g + 24 mg)
was studied in three groups (n = 8 each) of healthy volunteers under midazolam, flurbiprofen, and
paracetamol. Concentrations of curcuminoids and piperine after administration of capsules were
measurable, only after enzymatic hydrolysis, with a concentration, ranged from 136–176 ng/mL and
did not differ between the different trials with paracetamol, flurbiprofen, or midazolam [43].
Healthy male volunteers (n = 8) after 2 g/kg of oral pure curcumin presented very low serum levels
of curcumin (Cmax 0.006 ± 0.005 µg/mL at 1 h) but when 2 g/kg of pure curcumin are combined with
20 mg/kg of piperine the concentrations are significantly increased (0.18 ± 0.16 µg/mL at 0.75 h) [44].
4.2. Association of Curcumin and Lecithin
Phospholipid-phytochemical complexes are purported to improve gastrointestinal absorption of
poorly water-soluble phytochemicals via the amphipathic properties of the phospholipid [56].
A crossover study was carried out in healthy volunteers (n = 9) to measure plasma concentrations
of curcuminoids after supplementation with two dosages of formulated curcuminoids mixture with
lecithin (200 or 400 mg/day) and one dosage of non-formulated curcuminoid mixture (about 2 g/day).
No plasma peak of free curcumin was detected in any plasma samples. After enzymatic hydrolysis, the
concentrations of total curcuminoid were: (1) 206.9 ± 164.7 ng/mL at 2.7 ± 1 h after the administration
of 400 mg of formulated preparation, (2) 68.9 ± 50.8 ng/mL at 3.3 ± 1 h after the administration of
200 mg of formulated preparation, and (3) 14.4 ± 12.5 ng/mL at 6.9 ± 6.7 h after the administration
of non-formulated curcuminoid mixture. In respect of only curcumin, the concentrations (ng/mL)
were 50.3 ± 12.7 at 3.8 ± 0.6 h (400 mg of formulated preparation), 24.2 ± 5.9 at 4.2 ± 0.8 h (200 mg
of formulated preparation), and 9.0 ± 2.8 at 6.9 ± 2.2 h (crude curcumin powder) respectively. The
phospholipids formulation with lecithin increased the bioavailability of curcuminoids [45].
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In rats, peak plasma concentration and AUC were 5-fold higher for Meriva (a combination
of curcumin-phospholipids) than for unbound curcumin [57]. Another small single-dose study
demonstrated a comparable absorption of curcumin from 450 mg of Meriva and 4 g unbound of
Curcuma longa [58].
In a study, plasma and rectal tissue concentrations of curcuminoid were studied between standard
curcumin and phosphatidylcholine-complexed curcumin preparations. Plasma concentrations of
curcumin and the major curcuminoids in curcumin extracts were similar even though the doses were
4 g for pure curcumin and 400 mg for phosphatidylcholine-complexed curcumin [46].
4.3. Curcumin in Hydrophilic Nanoparticles
Colloidal nanoparticles show a 15-fold increase in the concentration of administered curcumin
as the result of an enhanced gastrointestinal absorption as a result of colloidal dispersion
(Sasaki et al., 2011).
A water-soluble curcumin formulation containing turmeric extract, a hydrophilic carrier (polyvinyl
pyrrolidone), cellulosic derivatives, and natural antioxidants (tocopherol and ascorbyl palmitate) was
compared to standard curcumin in healthy volunteers. This novel formulation with an increased
solubility provided a 46-fold increase in oral absorption as compared with the unformulated
curcumin [48].
Theracurmin is a highly absorptive form of curcumin produced using a technique of a micro-particle
and surface-controlled colloidal dispersion. A drinkable preparation of Theracurmin was studied, and
a clinical study in healthy humans (n = 24) was undertaken in order to compare the reached plasma
levels of curcumin after its ingestion vs. three other curcumin beverages sold in Japan. The blood
AUC (0–8 h) was found to be 1.5- to 4.0-fold higher and, in the same way, its Cmax was 1.8 to 3.8 times
higher with Theracurmin than with the other three kinds of curcumin. These findings demonstrate
that Theracurmin beverage shows the highest bioavailability among currently available beverages of
curcumin [49].
Repetitive Theracurmin was tested in pancreatic or biliary tract cancer patients in order to evaluate
its safety. Median plasma curcumin levels two h after Theracurmin administration were: 324 ng/mL
with a dose of 200 mg of curcumin and 440 ng/mL with a dose of 400 mg of curcumin. These results
were also combined with the evidence that the incidence of adverse events in cancer patients receiving
gemcitabine-based chemotherapy was not increased by this curcumin treatment [50]. The same group
tested this formulation also on healthy subjects (n = 9) with comparable results in terms of plasma
concentration of curcumin: 189 ± 48 ng/mL with a dose of 150 mg and 275 ± 67 ng/mL with a dose of
210 mg [51].
4.4. Curcumin in the Lipid-Based Formulation
Nanostructured lipid carriers stand tall over other strategies, due to their remarkable features:
(1) high bioavailability, (2) large loading capacity, (3) physical and chemical preservation, (4)
controlled release, (5) the absence of chemical cross-linking, (6) low toxicity, and (7) well tolerated in
multiple-dosage therapy.
Curcumin plasma concentration relationship was studied in both human volunteers and late-stage
osteosarcoma patients. The formulation employed was 650 mg of either solid lipid particles (130–195
mg of curcumin) or >390 mg of curcumin extract. No plasma peaks were found in the group which
underwent curcumin administration whereas with lipid vehicle curcumin concentration was proven to
be 22.43 ng/mL at 2.4 h. The same lipid formulation was administered in osteosarcoma patients with a
dose ranging from 2000 to 4000 mg reporting a maximum concentration between 30–40 ng/mL at 2–4 h.
The use of this kind of formulation suggested a continuous absorption into the bloodstream through
the colon [52].
Other studies on curcumin administration by lipids mixture or in complexation with phospholipids
indicated only a mild increase in the bioavailability [57,59,60].
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Liposomes are molecular assemblies like micro or nanospheres where lipids are organized in one
or more bilayers surrounding an aqueous environment. They can be loaded with both hydrophilic
and hydrophobic molecule, and to improve their stability they can be coated with polymers. In this,
in vitro study, the bioavailability of curcumin was investigated in chitosan-coated liposomes containing
curcumin as well as in loaded anionic liposomes. These two loading systems provided the same
percentage of curcumin for absorption (bioaccessibility), but chitosan-coated liposomes delivered a
higher concentration of bioactive curcumin (transformation). The results were a higher amount of
curcumin in the bile salt micelles for curcumin loaded into chitosan-coated liposomes which displayed,
indeed, a better bioavailability [15].
The potential application of sophorolipids, glycolipids composed of a polar sophorose group
and a nonpolar fatty acid group, as biosurfactants for forming curcumin-loaded colloidal delivery
systems was evaluated. The nanoparticles displayed a relatively high encapsulation efficiency (82%)
and loading capacity (14%) for curcumin. In vivo bioavailability of curcumin was investigated by oral
administration (100 mg/kg as pure curcumin or as curcumin micelles) to 12 male Sprague−Dawley rats.
Curcumin oral administration with these nanoparticles led to a significantly higher (6-fold) and more
prolonged level of curcumin in the blood of the rats than in the form of free crystals. These results
were related to the ability of sophorolipid micelles to increase the solubilization of the curcumin in the
mixed phase [61].
4.5. Curcumin in a Micellar System
Curcumin absorption and excretion kinetics were investigated in a single-blind crossover study
with healthy female and male subjects comparing 500 mg formulation of native curcumin, curcumin
incorporated into a micronised powder, or in liquid micelles. Micronized curcumin and micelles
showed a significantly higher concentration of curcumin than curcumin powder both in plasma and in
urine. Curcumin Cmax in plasma was 7.1 nmol/L at 4 h, 41.6 nmol/L at 1.4, 3228 nmol/L at 1.1; whereas,
in urine were 5.1 nmol/g creatine, 70.6 nmol/g creatine, and 753.4 nmol/g creatine in native curcumin,
micronised powder, and liquid micelles respectively. In the same way, also demethoxycurcumin and
bis-demethoxycurcumin were quantified [40].
Glioblastoma patients (n = 13) ingested 70 mg of micellar curcuminoids three times per
day for four days (total amount of 689 mg curcumin, 134 mg demethoxycurcumin, and 17 mg
bis-demethoxycurcumin) before brain surgery. Tumor and blood samples were taken during the
surgery and analyzed for total curcuminoid concentrations: 56 pg/mg in resected tumors (range 9–151),
and 253 ng/mL (range 129–364) in the blood. However, the intra-tumoral concentration might not be
sufficient to cause significant localise antitumor effects [53].
4.6. Curcumin in Chitosan Nanoparticles
An in vivo pharmacokinetics study was done in albino rats to understand the differences between
curcumin release by simple suspension, chitosan microspheres and ascorbic acid coated chitosan
microspheres. The oral bioavailability of curcumin was enhanced to a great extent with microspheres
containing ascorbic acid compared to pure curcumin and plain microspheres: 1.139 ± 0.118 vs. 0.512
± 0.020 and 0.655 ± 0.028 µg/mL respectively. The presence of this acid might protect the drug from
pH-mediated chemical degradation, thus improving the fraction of curcumin that can be absorbed. In
that way, unmodified curcumin can reach the colon, after the dissolution of the delivery system and
the degradation of chitosan by microbial flora [62].
Amorphous ternary nano complex of curcumin-chitosan-hypromellose exhibited superior (1)
physical stability after 12-month storage, (2) dissolution characteristics, (3) solubility enhancement in
simulated gastrointestinal fluids, and (4) minimal cytotoxicity towards human gastric epithelial cells.
This nanocarrier may be promising to enhance curcumin solubility and thus its bioavailability [63].
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Another system developed was a polyelectrolyte complex nanoparticles, with chitosan and
acylated cruciferin. They demonstrated an encapsulation efficiency of 72% and a controlled in vitro
release for 6 h of curcumin, using simulated gastro and intestinal fluids [64].
4.7. Miscellaneous
Healthy human subjects (n = 15) were administered with 500 mg Cureit, a bioavailable form of
curcumin prepared by using polar-nonpolar-sandwich technology starting from complete natural
turmeric matrix. The pharmacokinetic study results are also supported that Cureit can enhance the
absorption of curcumin by the registration of high AUC and Cmax values (527.1 ng h/mL, 74.3 ng/mL).
Furthermore, this study simultaneously characterized and quantitatively in human plasma determined
the metabolites of curcumin such as tetrahydrocurcumin, hexahydrocurcumin, octahydrocurcumin,
curcumin glucuronide, curcumin sulfate along with the other curcuminoids [54].
The characteristics and bioavailability of ethyl cellulose–citric acid microspheres loading curcumin
were studied in healthy rats (n = 40). The drug concentration was 4-fold higher than pure curcumin
with a maximum peak value (42.51 ng/mL) at 8 h. Moreover, the peak time was delayed for 7.5 h [65].
BCM-95CG (Biocurcumax™) is a simple and cost-effective formulation which consisted of a
mixture of sesquiterpenoids present in turmeric (less than 5% in essential oils especially Ar-turmerone)
and the curcuminoids providing an enhanced bioavailability. Healthy subjects under the age group
of 28–50 (n = 11) were recruited for the study and divided into three separate groups: (1) group 1
(n = 4) consumed 4 × 500 mg capsules of Biocurcumax™; (2) group 2 (n = 4) consumed 2000 mg
control curcumin; and (3) group 3 (n = 3) consumed 2000 mg curcumin-lecithin-piperine formula.
The proprietary formulation Biocurcumax™ largely enhance the bioavailability of curcumin. The
mean plasma concentration of curcumin from Biocurcumax™ was 689.18 ng/g at 4.67 h whereas from
curcumin-lecithin-piperine formula reached a peak value of 344.32 ng/g at 3.5 h and control curcumin
149.8 ng/g at two h. The main differences found in the proprietary formulation vs. curcumin were (1)
higher concentrations which gradually decreased even at 8 h some residual curcumin remained in the
blood; (2) a possible extra-intestine absorption; and (3) due to its long presence in circulation may also
modulate the activity of P-glycoprotein and the Phase II enzymes. Results from that pilot study indicate
that curcumin is absorbed early and retained longer from the BCM-95CG (Biocurcumax™) showing
a better pharmacokinetic profile compared both to pure curcumin and curcumin-lecithin-piperine
formula [55].
Curcumin solubility can be enhanced through whey protein-based encapsulation giving a higher
bioavailability and bio-efficacy by enhancing curcumin solubility with a slow release: about 50% at
24 h and 70% at 48 h (in vitro evidence) [66].
5. Conclusions
Curcumin has been used for thousands of years in Asian traditional medicine for its
anti-inflammatory and anti-oxidative profile. Although oral curcumin supplementation has shown
therapeutic efficacy in many clinical trials, its nutraceutical activities are counteracted by low absorption,
restricted bioavailability, fast metabolism, and elimination. Some pharmaceutical technology or peculiar
combination with other compounds, such as piperine or lecithin, were found to enhance its solubility,
extend the residence in plasma, and improve the pharmacokinetic profile and the cellular uptake.
Depending on the dose and the pathophysiological condition of the subject, the administration of
crude curcumin showed a wide range in serum concentrations (1–3200 ng/mL) and in some cases, the
concentration is even not determinable. Different novel delivery systems such as solid lipid particle,
micellar system, or hydrophilic nanoparticles could increase curcumin concentration up to 15–20 fold.
The determination of curcumin pharmacokinetic profile seems to be challenging, in many cases, due to
low circulant concentrations. Thus, the choice of an advanced analytical technique, such as LC-MS/MS,
should be considered.
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To conclude, the health potential of curcumin, that is undoubtedly assessed, has to be always
evaluated by correlation with a well-defined way of administration, in order to achieve the
optimal efficacy.
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